YMTX
NASDAQYumanity Therapeutics Inc.
Latest news
25 items- 13D/GSEC Form SC 13G filed by Yumanity Therapeutics Inc.SC 13G - KINETA, INC./DE (0001445283) (Subject)
- 13D/GSEC Form SC 13D/A filed by Yumanity Therapeutics Inc. (Amendment)SC 13D/A - KINETA, INC./DE (0001445283) (Subject)
- 13D/GSEC Form SC 13G/A filed by Yumanity Therapeutics Inc. (Amendment)SC 13G/A - KINETA, INC./DE (0001445283) (Subject)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- INSIDERBartoszek Raymond J. bought $9,950 worth of shares (2,250 units at $4.42), increasing direct ownership by 15% to 17,206 units (SEC Form 4)4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERPhilips Craig W. bought $9,812 worth of shares (3,000 units at $3.27), increasing direct ownership by 5% to 60,811 units (SEC Form 4)4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERIadonato Shawn bought $17,398 worth of shares (5,000 units at $3.48), increasing direct ownership by 0.75% to 675,230 units (SEC Form 4)4 - KINETA, INC./DE (0001445283) (Issuer)
- SECSEC Form EFFECT filed by Yumanity Therapeutics Inc.EFFECT - KINETA, INC./DE (0001445283) (Filer)
- SECSEC Form 424B3 filed by Yumanity Therapeutics Inc.424B3 - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECSEC Form S-3 filed by Yumanity Therapeutics Inc.S-3 - KINETA, INC./DE (0001445283) (Filer)
- SECSEC Form 10-Q filed by Yumanity Therapeutics Inc.10-Q - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECSEC Form D filed by Yumanity Therapeutics Inc.D - KINETA, INC./DE (0001445283) (Filer)
- SECSEC Form 8-K filed by Yumanity Therapeutics Inc.8-K - KINETA, INC./DE (0001445283) (Filer)
- INSIDERFoote Marion R exercised 4,443 shares at a strike of $0.14, increasing direct ownership by 3% to 143,204 units (SEC Form 4)4 - KINETA, INC./DE (0001445283) (Issuer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECSEC Form 424B5 filed by Yumanity Therapeutics Inc.424B5 - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- SECYumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- INSIDERSEC Form 4: Philips Craig W. bought $8,495 worth of shares (3,500 units at $2.43), increasing direct ownership by 6% to 57,811 units4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4: Kenny Pauline bought $3,870 worth of shares (1,500 units at $2.58), increasing direct ownership by 9% to 18,448 units4 - KINETA, INC./DE (0001445283) (Issuer)
YMTX FAQ
6 questionsWhat does Yumanity Therapeutics Inc. do?
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is...Where does YMTX stock trade?
Yumanity Therapeutics Inc. (YMTX) is listed on NASDAQ.What sector and industry is YMTX in?
Yumanity Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Yumanity Therapeutics Inc. go public?
Yumanity Therapeutics Inc. (YMTX) completed its IPO in 2016.What companies are similar to YMTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare YMTX side-by-side with any of them on Quantisnow.How can I track YMTX on Quantisnow?
Quantisnow aggregates Yumanity Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YMTX to receive live email and push alerts on every new disclosure.